Question special
Chief Resident

This trial included both diabetic and non diabetic patients. If the purpose of doing this study was to prove that SGLT2i have CV benefits irrespective of presence or absence of diabetes wouldn't the results be more valid if the diabetics were excluded and study was done only in non-diabetic HFrEF to eliminate possible bias if any.
Although I know sub group analysis showed that diabetics and non diabetics had equal benefi. Did the Kaplan Myers curves for both subgroups show reduced primary outcomes as well specifically mortality reduction?

Thank you..